When VSD+ is used, excess heat or gas is pumped into the barns to speed up the process, though it can still take hours to kill animals. VSD+ has been increasingly used by the animal agriculture ...
Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...
RxSight’s management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast of the presentation will ...
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable ...
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash ...
About OrthoPediatrics Corp. Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most ...
Portage, Michigan, March 25, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2025 Annual Meeting of Shareholders is scheduled as follows: Thursday, May 8, 2025 – 9:30 a.m. Eastern Time ...
Expands market-leading position with new best-in-class bunion technologies. PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "C ...
SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...
IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...
Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million for the full year ended December 31, 2024 relating to the Company’s ...
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World’s Premier Cancer Research Forum
Rakovina will present two abstracts at the meeting, the first: Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence, explores the use of artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback